FIELD: medicine.
SUBSTANCE: invention relates to a compound having a structure: X-Y-Z; where: X is polypeptide at least 80% identical to a sequence with SEQ ID NO: 3; Z is a molecule delivering to bones, containing 4 or more acidic amino acid residues, polyphosphate, aminoadipine acid, alendronate, and/or bisphosphonate; and Y is a linker containing polypeptide at least 80% identical to a sequence with amino acid residues 35-46 of full-sized peptide relative to parathyroid hormone; or its pharmaceutically acceptable salt, as well as to a method for the treatment of bone fracture.
EFFECT: drug delivery system is developed, which corrects some side effects caused by a free anabolic drug, such as high concentration of calcium in blood.
15 cl, 27 dwg, 1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
| RECOMBINANT MODIFIED FIBROBLAST GROWTH FACTORS AND THEIR THERAPEUTIC USE | 2018 |
|
RU2811435C2 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
| Cys80-CONJUGATED IMMUNOGLOBULINS | 2016 |
|
RU2756101C2 |
| ANTIBODIES TARGETING BONE | 2018 |
|
RU2801206C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| NEOANTIGENS AND THEIR APPLICATION | 2019 |
|
RU2805196C2 |
| TAU-PEPTIDE IMMUNOGENIC CONSTRUCTS | 2018 |
|
RU2798972C2 |
| ANTIBODY SPECIFICALLY BINDING TO ICAM-1 AND ITS USE | 2019 |
|
RU2789757C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
